Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509769 · ClinicalTrials.gov registry record · Phase 2
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00509769 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 112 participants.
The verdict
NCT00509769, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Interventions
- DRUG Trastuzumab emtansine [Kadcyla]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509769
The ClinicalTrials.gov registry entry for NCT00509769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trastuzumab emtansine [Kadcyla] is the first listed.
NCT00509769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509769 about?
NCT00509769 is a clinical study titled "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer". This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
What is the current status of trial NCT00509769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2007-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00509769?
The interventions under investigation include: Trastuzumab emtansine [Kadcyla] (DRUG).
Who is sponsoring clinical trial NCT00509769?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.